@article{67757a3381ac423a93f4f45a2bb6af44,
title = "Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer",
abstract = "Purpose: To review the management of metastatic upper tract urothelial carcinoma (UTUC) including recent advances in targeted and immune therapies as an update to the 2014 joint international consultation on UTUC, co-sponsored by the Soci{\'e}t{\'e} Internationale d{\textquoteright}Urologie and International Consultation on Urological Diseases. Methods: A PubMed database search was performed between January 2013 and May 2016 related to the treatment of metastatic UTUC, and 54 studies were selected for inclusion. Results: The management of patients with metastatic UTUC is primarily an extrapolation from evidence guiding the management of metastatic urothelial carcinoma of the bladder. The first-line therapy for metastatic UTUC is platinum-based combination chemotherapy. Standard second-line therapies are limited and ineffective. Patients with UTUC who progress following platinum-based chemotherapy are encouraged to participate in clinical trials. Recent advances in genomic profiling present exciting opportunities to guide the use of targeted therapy. Immunotherapy with checkpoint inhibitors has demonstrated extremely promising results. Retrospective studies provide support for post-chemotherapy surgery in appropriately selected patients. Conclusions: The management of metastatic UTUC requires a multi-disciplinary approach. New insights from genomic profiling using targeted therapies, novel immunotherapies, and surgery represent promising avenues for further therapeutic exploration.",
keywords = "Anti-PD-1, Anti-PD-L1, Chemotherapy, Immune checkpoint inhibitors, Immunotherapy, Targeted therapy, Upper tract urothelial carcinoma (UTUC)",
author = "Pham, {M. N.} and Apolo, {A. B.} and {De Santis}, M. and Galsky, {M. D.} and Leibovich, {B. C.} and Pisters, {L. L.} and Siefker-Radtke, {A. O.} and G. Sonpavde and Steinberg, {G. D.} and Sternberg, {C. N.} and Tagawa, {S. T.} and Weizer, {A. Z.} and Woods, {M. E.} and Milowsky, {M. I.}",
note = "Funding Information: MN Pham, AB Apolo, BC Leibovich, LL Pisters, AZ Weizer, ME Woods have no conflicts of interest. M De Santis has received research funding from Pierre Fabre Oncology and honoraria and consultation fees from Amgen, Astellas, Bayer, Celgene, Dendreon, Eisai Inc., ESSA, Ferring, GSK, Janssen Cilag, Merck, Novartis, Pfizer, Pierre Fabre Oncology, Roche, Sanofi Aventis, Shionogi, Synthon, Takeda and Teva/OncoGenex; MD Galsky has received research funding (to institution) from Merck, Genentech, BMS, Celgene, Novartis, and Dendreon. He is a member of the advisory boards for Merck, Genentech, and Novartis; AO Siefker-Radtke is a consultant and scientific advisor for: AstraZeneca, Genentech, Janssen, Eisai, and Merck. She receives research funding (to institution) from Millenium/Takeda, Genentech, Janssen, and AstraZeneca; G Sonpavde receives research support from Onyx, Bayer, Merck, Celgene, Pfizer, and Boehringer-Ingelheim. He is on the advisory board and/or is a consultant for Merck, Genentech, Sanofi, Bayer, Pfizer, Agensys, Novartis, and Argos. He is an author for UpToDate and speaker for Clinical Care Options; GD Steinberg is a consultant, scientific advisor, and/or investigator for: Photocure, Taris Biomedical, Cold Genesys, Heat Biologics, Roche/Genentech, UroGen, Merck, Karl Storz, and Telesta; CN Sternberg is a consultant, scientific advisor, and/or investigator for Merck, BMS, Oncogenex, and Lilly; ST Tagawa has received honoraria from Sanofi, Astellas, Janssen, Dendreon, Bayer, and Genentech and research funding (to institution) from Sanofi, Astellas, Janssen, Genentech, Lilly, Dendreon, Progenics, Millennium, Amgen, Bayer, Rexahn, and Inovio; MI Milowsky has received research funding (to institution) from BIND Therapeutics, Dendreon, Exelixis, Johnson & Johnson, Mirati Therapeutics, Pfizer, Cerulean Pharma, Merck, Seattle Genetics, Acerta Pharma, BioClin Therapeutics, and Roche/Genentech. Publisher Copyright: {\textcopyright} 2016, Springer-Verlag Berlin Heidelberg.",
year = "2017",
month = mar,
day = "1",
doi = "10.1007/s00345-016-1885-4",
language = "English (US)",
volume = "35",
pages = "367--378",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "3",
}